Olsalazine Sodium

CHEMBL1201013 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

346.2 g/mol

LogP

—

Phase

4

A sodium salt form of olsalazine with the same therapeutic properties. An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Masse moléculaire

346,2000 g/mol

TPSA

145,00 Å²

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C([O-])c1cc(/N=N/c2ccc(O)c(C(=O)[O-])c2)ccc1O.[Na+].[Na+]

InChI

InChI=1S/C14H10N2O6.2Na/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22;;/h1-6,17-18H,(H,19,20)(H,21,22);;/q;2*+1/p-2/b16-15+;;

Molecular Formula

C14H8N2Na2O6

HBD / HBA

2 / 8

Liaisons Rotatives

4

Atomes Lourds

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A sodium salt form of olsalazine with the same therapeutic properties. An anti-inflammatory delivering mesalamine directly to the colon for ulcerative colitis maintenance.

Yes, Olsalazine Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201013. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135413505. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Olsalazine Sodium sur PillFYI

Structure

Données Clés

Formule: C14H8N2Na2O6
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.